Using Cerebrospinal Fluid to Track Glioma Tumor Evolution

Diffuse gliomas, the most common primary brain tumors, are often highly aggressive and are associated with poor outcomes and limited effective treatment options. The location of these tumors makes genetic profiling difficult and requires invasive brain surgery for tissue collection. Furthermore, because these tumors undergo several genomic alterations throughout their development, repeat biopsies are often […]

Read More

Cannabis May Impact Tumor Response to Immune Checkpoint Inhibitors

Immunotherapy with immune checkpoint inhibitors targeting PD-1 and PD-L1 is now a standard of care for many solid tumors. These agents are highly effective at stimulating anticancer immune responses, resulting in durable responses. Recently, many cancer patients have begun to use medical cannabis as an adjunct to treatment in order to manage disease symptoms, including […]

Read More

Benefit of Watch-and-Wait Remains Unclear for Rectal Cancer

Patients with localized rectal cancer are most commonly treated with neoadjuvant therapy (NAT) followed by total mesorectal excision (TME). While this combination is highly effective in reducing risk of metastases and prolonging survival, surgery may be associated with significant morbidity and decreased quality of life. Thus, there is a growing need to develop alternate treatment […]

Read More

primelines-nsclc-asco-updates-2017-prime-oncology

SCLC Transformation of EGFR-Mutated NSCLC

Histologic transformation of EGFR-mutant non-small cell lung cancer (NSCLC) to small cell lung cancer (SCLC) is a rare mechanism of acquired resistance to EGFR-targeted tyrosine kinase inhibitors (TKIs) that occurs in approximately 3% to 10% of EGFR mutant NSCLCs. However, the natural history and clinical course of SCLC after transformation from NSCLC is poorly understood. […]

Read More

metastatic pleural mesothelioma

Avelumab Active in Advanced Mesothelioma

Malignant plural mesothelioma is a rare, incurable cancer with limited treatment options and poor prognosis. First-line treatment with cisplatin plus pemetrexed is the standard of care, but this is associated with an overall survival (OS) of only 12.1 months. Addition of bevacizumab to this chemotherapy regimen further improves survival in pleural mesothelioma and may be […]

Read More

GnRH Antagonist for Optimal Ovarian Suppression in Breast Cancer

Ovarian function suppression (OFS) is an important part of endocrine treatment for premenopausal women with advanced and early hormone receptor (HR)-positive breast cancer. Achievement of postmenopausal status through OFS is mandatory for treatment with aromatase inhibitors in premenopausal patients. Gonadotropin-releasing hormone (GnRH) agonists (eg, triptorelin, goserelin, leuprolide) are commonly used for ovarian suppression in premenopausal […]

Read More

Breast cancer

Adjuvant T-DM1 New Standard in Early HER2-Positive Breast Cancer

The standard of care for women with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer has evolved significantly in recent years as new agents and combinations have emerged that improve upon standard adjuvant and neoadjuvant treatment with trastuzumab alone. Patients with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant chemotherapy […]

Read More

FDA Wraps Up 2018 With Approval of Six New Anticancer Indications

2018 was another banner year for approvals by the United States Food and Drug Administration (FDA), with more than 50 new indications being awarded to immunotherapy, targeted therapies, chemotherapies, biosimilar antibodies, and diagnostic tests. Once again, immunotherapy took center stage with new indications for PD-1 and PD-L1 inhibitors across different tumor types. The most notable […]

Read More

Multiple myeloma cells

Daratumumab-Rd Regimen New Standard for Transplant Ineligible Myeloma

  The majority of patients with newly diagnosed multiple myeloma are treated with a triplet of bortezomib, lenalidomide, and dexamethasone (VRd) induction therapy, followed by transplant and maintenance therapy. However, some patients, in particular the elderly, are ineligible for transplant due to frailty or comorbidities. For these patients, treatment with regimens such as VRd or […]

Read More